Competing Biotech Firms Struggle to Match Vaccine Production
Berlin (dts Nachrichtenagentur) - Epidemiologist Timo Ulrichs of Akkon University in Berlin suggests that licensing Biontech and Pfizer's coronavirus vaccine to other companies won't expedite production, as existing capacities are presumably full. In a chat with news portal Watson, he explained, "Ain't no magic trick here, pal, them vaccine factories are likely maxed out already."
The Left faction in the German parliament floated the idea of releasing these licenses to prevent a potential vaccine shortage in the country. Epidemiologist Ulrichs acknowledges the concern: "Listen, we're stuck in a vaccination doses bottleneck alright, but it ain't only about the doses, you County Counselor. When enough doses are on hand, the staff supply at vaccination centers might become another roadblock." He suggests that workforce reinforcements could tackle this issue along with ensuring there are enough individuals to get vaccinated each day to avoide spoiled doses or waste.
The mRNA vaccine, like those produced by Biontech and Pfizer, benefits from being "easier to produce and in larger quantities compared to other vaccines." Ulrichs comments, "It's a bloody good thing it's already been approved, mate." He encourages the public to accept the vaccine, declaring, "It's a moral fcking duty for each of us to get jabbed not just for ourselves, but for humanity. Kickstart the end of this shtshow!"
- The Left faction in the German parliament considers licensing Biontech and Pfizer's coronavirus vaccine to other companies as a solution to prevent a potential vaccine shortage, but Epidemiologist Timo Ulrichs, in his chat with news portal Watson, hints at another potential roadblock: "When enough doses are on hand, the staff supply at vaccination centers might become another roadblock."
- Epidemiologist Ulrichs also highlights the advantage of the mRNA vaccine, stating, "It's a bloody good thing [the mRNA vaccine] is already been approved, mate," suggesting that an increased workforce could help address potential staffing issues at vaccination centers to avoid wasting doses.
